Mergers & acquisitions
Gemphire will enter into the reverse merger following a strategic review of its options.
Eurofins Scientific, a world leader in biopharmaceutical testing acquired Alphora Research Inc. to support Eurofins’ extensive drug development platform.
Eurofins Scientific, a world leader in biopharmaceutical testing acquired Amatsigroup SAS to support Eurofins’ extensive drug development platform.
Gimv, Sofinnova and Gilde Healthcare announced the sale of biopharmaceutical company Breath Therapeutics.
The sale of Germany-based Breath comes after the company launched two late-stage trials assessing its lead product as a treatment for a disease that affects lung transplant patients.
MyoKardia, Inc. announced updates related to its hypertrophic cardiomyopathy treatment portfolio, including lead therapeutic candidate, mavacamten.
Largest off-the-shelf diploid KO library, over 2,800 cell lines
Invitae Corporation, a leading medical genetics company, has announced that it has entered into a definitive agreement to acquire Jungla Inc.
Acquired assets from NCARDIA AG include IP portfolio, IPSC-based cellular products and an experienced stem cell biology team
The M&A moves are expected to increase the oncology pipelines of both companies.
PRESS RELEASES